OptimizeRx (OPRX) Net Income towards Common Stockholders (2010 - 2026)

OptimizeRx has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$495000.0 for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$495000.0, up 77.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (up 144.36% YoY), and the FY2025 annual result was $5.1 million, up 125.52% from the prior year.
• Net Income towards Common Stockholders came in at -$495000.0 for Q1 2026 at OptimizeRx, down from $5.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $5.0 million in Q4 2025 to a low of -$11.7 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$3.5 million (2022), against an average of -$3.1 million.
• Across the five-year window, Net Income towards Common Stockholders sank 8790.01% in 2022 and surged 6535.9% in 2025, its largest moves.
• OptimizeRx's Net Income towards Common Stockholders stood at -$325836.0 in 2022, then sank by 3503.04% to -$11.7 million in 2023, then jumped by 99.34% to -$78000.0 in 2024, then soared by 6535.9% to $5.0 million in 2025, then plunged by 109.86% to -$495000.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$495000.0 (Q1 2026), $5.0 million (Q4 2025), and $779000.0 (Q3 2025), per Business Quant data.